Archive for month: July, 2019

You are here: Home / 2019 / July

ChemoCentryx, Inc. (CCXI) EPS Estimated At $-0.21; Blackrock Muniyield California Quality Fund Has 0.95 Sentiment

/0 Comments/in /by

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Analysts expect ChemoCentryx, Inc. (NASDAQ:CCXI) to report $-0.21 EPS on August, 8.They anticipate $0.07 EPS change or 50.00% from last quarter’s $-0.14 EPS. After having $-0.23 EPS previously, ChemoCentryx, Inc.’s analysts see -8.70% EPS growth. The stock increased 0.13% or $0.01 during the last trading session, reaching $7.75. About 43,116 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 11.16% since July 29, 2018 and is uptrending. It has outperformed by 6.73% the S&P500. Some Historical CCXI News: 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018

Blackrock Muniyield California Quality Fund Inc (MCA) investors sentiment decreased to 0.95 in Q1 2019. It’s down -1.28, from 2.23 in 2018Q4. The ratio dived, as 18 institutional investors increased or started new holdings, while 19 sold and reduced their stock positions in Blackrock Muniyield California Quality Fund Inc. The institutional investors in our database now possess: 5.74 million shares, down from 6.04 million shares in 2018Q4. Also, the number of institutional investors holding Blackrock Muniyield California Quality Fund Inc in top ten holdings increased from 0 to 1 for an increase of 1. Sold All: 7 Reduced: 12 Increased: 14 New Position: 4.

Investors sentiment increased to 1.44 in 2019 Q1. Its up 0.51, from 0.93 in 2018Q4. It increased, as 12 investors sold ChemoCentryx, Inc. shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Matarin Mngmt Ltd Limited Liability Company has invested 0.08% in ChemoCentryx, Inc. (NASDAQ:CCXI). Walleye Trading Ltd Liability Corp holds 14,800 shares or 0% of its portfolio. Dimensional Fund L P owns 1.19M shares. Consonance Cap L P reported 1.67M shares or 1.46% of all its holdings. Pnc Fincl Services Group reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). The California-based Charles Schwab Invest Mgmt has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Bvf Il accumulated 1.46M shares or 2.28% of the stock. Alps Advisors invested in 122,039 shares or 0.01% of the stock. Dorsey Wright Associates owns 585 shares. Smith Asset Grp Limited Partnership has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 21,617 shares. Sectoral Asset Mngmt Incorporated reported 0.03% in ChemoCentryx, Inc. (NASDAQ:CCXI). 4,696 were reported by Bnp Paribas Arbitrage. Millennium Mgmt Limited Liability Co reported 49,812 shares or 0% of all its holdings. State Common Retirement Fund stated it has 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). State Of Wisconsin Inv Board invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI).

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint – Benzinga” on July 26, 2019, also Finance.Yahoo.com with their article: “Hedge Funds Have Never Been More Bullish On ChemoCentryx Inc (CCXI) – Yahoo Finance” published on May 09, 2019, Seekingalpha.com published: “InflaRx downdraft engulfs ChemoCentryx, down 28% premarket – Seeking Alpha” on June 05, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Globenewswire.com and their article: “ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights – GlobeNewswire” published on May 06, 2019 as well as Globenewswire.com‘s news article titled: “ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors – GlobeNewswire” with publication date: March 28, 2019.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $449.87 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 6 analyst reports since February 11, 2019 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, March 27 by FBR Capital. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, March 12. Leerink Swann initiated the stock with “Buy” rating in Thursday, February 14 report.

BlackRock MuniYield California Quality Fund, Inc. is a closed ended fixed income mutual fund launched by BlackRock, Inc. The company has market cap of $492.69 million. It is managed by BlackRock Advisors, LLC. It has a 71.24 P/E ratio. The fund invests in fixed income markets.

Mariner Investment Group Llc holds 2.49% of its portfolio in BlackRock MuniYield California Quality Fund, Inc. for 136,771 shares. Hollencrest Capital Management owns 747,326 shares or 1.32% of their US portfolio. Moreover, Dakota Wealth Management has 0.76% invested in the company for 63,599 shares. The New York-based Karpus Management Inc. has invested 0.45% in the stock. Rivernorth Capital Management Llc, a Illinois-based fund reported 488,489 shares.

The stock increased 0.28% or $0.04 during the last trading session, reaching $14.32. About 5,437 shares traded. BlackRock MuniYield California Quality Fund, Inc. (MCA) has risen 5.16% since July 29, 2018 and is uptrending. It has outperformed by 0.73% the S&P500.

More notable recent BlackRock MuniYield California Quality Fund, Inc. (NYSE:MCA) news were published by: Seekingalpha.com which released: “BlackRock MuniYield California Insured Fund declares $0.0460 dividend – Seeking Alpha” on July 02, 2019, also Seekingalpha.com with their article: “Shopify: A Multibagger That I Don’t Own Anymore – Seeking Alpha” published on February 06, 2019, Seekingalpha.com published: “Shopify: Expensive Beyond Reason – Seeking Alpha” on September 11, 2018. More interesting news about BlackRock MuniYield California Quality Fund, Inc. (NYSE:MCA) were released by: Finance.Yahoo.com and their article: “Have Insiders Been Buying Murray Cod Australia Limited (ASX:MCA) Shares? – Yahoo Finance” published on July 16, 2019 as well as Seekingalpha.com‘s news article titled: “In Search Of Income: Municipal Bond CEFs (Part II) – Seeking Alpha” with publication date: January 20, 2015.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

Agency Directory: LiveWorld – Partner Content – MM&M

/0 Comments/in /by

Publish Date

LiveWorld provides a full range of agency services and software that help pharma brands build and operate effective, compliant social media and digital programs that deliver desired behavior changes and positively impact business goals. We help our clients create emotional connections with customers resulting in action, sales and advocacy.

2018 Revenue

$4.3 million

2018 Total Clients

AOR: 64

Capabilities/Services Offered

  • Consumer
  • OTC/wellness
  • Media planning + buying
  • Digital
  • Working with health tech startups or innovative tech
  • Market research/data/analytics

Current Client List

  • AbbVie, AS1(Ankylosing Spondylitis), PsoriasisSpeaks, StartswithSkin, NoBSAboutHS.com (Hidradenitis Suppurativa), AbbVie Corporate, Canada Corporate, Humira Complete Answers, SpeakEndo.com, Orilissa, TakeonEndo, Synthroid & Face HepC
  • AMAG, Intrarosa
  • Amgen/Novartis, Aimovig, SpeakYourMigraine
  • AstraZeneca, Crestor, Nexium, Tagrisso, Farxiga, Protect Little Lungs, e-Asthma. Save Your Breath & The 4th Shift
  • Bristol-Myers Squibb, BMS Corporate, Discover I-O, BMS Immuno-Oncology & Orencia 
  • Cancer Treatment Centers of America 
  • Consumer Healthcare Products Association
  • Cord Blood Registry
  • Pfizer, Advil Cold & Allergy, Advil, Caltrate, Centrum, Chapstick, Children’s Advil, Emergen-C, Imedeen, Nexium24HR, Meet Meningitis, Preparation H, Robitussin, Story Half Told (Cancer), Thermacare, Know Pneumonia (Prevnar 13), Our Hemophilia Community, HemMobile & AcroTracker, Get Old & Pfizer Corporate
  • Rite Aid
  • Zoetis, APOQUEL, Catisphere (Feline Revolution), The Pet Effect, Corporate, Cerenia, Convenia, Cytopoint, Diroban, K-9 Courage, Proheart 6, Canine Revolution, Rimadyl, Sileo & Simparica

Campaign

In an effort to combat generics, AbbVie launched a social media presence to boost preference for Synthroid the #1 branded drug for hypothyroidism, a condition where the thyroid gland doesn’t make enough thyroxine. The campaign uses a combination of condition awareness content and treatment education informing how and when patients can use Synthroid effectively.

Contact Information

4340 Stevens Creek Blvd STE 101
San Jose, CA 95129


Recommended For You



Source link

$-0.15 EPS Expected for XBiotech Inc. (XBIT); Steven Madden LTD. (SHOO) Sellers Increased By 6.29% Their Shorts

/0 Comments/in /by

Steven Madden, Ltd. (NASDAQ:SHOO) Logo

Analysts expect XBiotech Inc. (NASDAQ:XBIT) to report $-0.15 EPS on August, 8.After having $-0.16 EPS previously, XBiotech Inc.’s analysts see -6.25% EPS growth. The stock decreased 1.42% or $0.1 during the last trading session, reaching $6.96. About 28,598 shares traded. XBiotech Inc. (NASDAQ:XBIT) has risen 114.12% since July 29, 2018 and is uptrending. It has outperformed by 109.69% the S&P500. Some Historical XBIT News: 16/04/2018 – Press Release: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC; 20/04/2018 – DJ XBiotech Inc, Inst Holders, 1Q 2018 (XBIT); 02/04/2018 – XBIOTECH – WILL USE ITS TECHNOLOGY TO ADVANCE DEVELOPMENT OF TRUE HUMAN(TM )ANTI-NY-ESO-1 MONOCLONAL ANTIBODY, 12D7; 22/05/2018 – XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis; 16/04/2018 – XBIOTECH INC – CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES; 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 02/04/2018 – XBIOTECH INC – OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG, A SWISS BIOTECHNOLOGY COMPANY

Steven Madden LTD. (NASDAQ:SHOO) had an increase of 6.29% in short interest. SHOO’s SI was 3.40M shares in July as released by FINRA. Its up 6.29% from 3.20 million shares previously. With 548,500 avg volume, 6 days are for Steven Madden LTD. (NASDAQ:SHOO)’s short sellers to cover SHOO’s short positions. The stock decreased 1.35% or $0.46 during the last trading session, reaching $33.67. About 258,703 shares traded. Steven Madden, Ltd. (NASDAQ:SHOO) has declined 3.10% since July 29, 2018 and is downtrending. It has underperformed by 7.53% the S&P500. Some Historical SHOO News: 20/04/2018 – Steven Madden Sees FY18 Adj EPS $2.60-Adj EPS $2.67; 20/04/2018 – STEVEN MADDEN LTD SHOO.O SEES FY 2018 SHR $2.55 TO $2.62; 03/04/2018 – Steven Madden to Expand Board Size to 9 Members From 8, Effective April 2; 20/04/2018 – Steven Madden Adjusts FY18 View To EPS $2.55-EPS $2.62; 20/04/2018 – STEVEN MADDEN LTD SHOO.O SEES FY 2018 SALES UP 5 TO 7 PCT; 15/05/2018 – Balyasny Asset Management LLC Exits Position in Steven Madden; 03/04/2018 – STEVEN MADDEN LTD SAYS ON MARCH 30, CO’S BOARD DETERMINED TO EXPAND SIZE OF BOARD FROM EIGHT MEMBERS TO NINE MEMBERS – SEC FILING; 20/04/2018 – Steven Madden 1Q Net Income Climbs 42%; 22/04/2018 – DJ Steven Madden Ltd, Inst Holders, 1Q 2018 (SHOO); 20/04/2018 – STEVEN MADDEN SEES FY ADJ EPS $2.60 TO $2.67, EST. $2.68

More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Finance.Yahoo.com which released: “What Kind Of Investor Owns Most Of XBiotech Inc. (NASDAQ:XBIT)? – Yahoo Finance” on July 16, 2019, also Nasdaq.com with their article: “Medical Research Council Funds Phase 2 Multi-Center Study of XBiotech’s Bermekimab in Advanced Cancer Patients – Nasdaq” published on July 09, 2019, Nasdaq.com published: “XBiotech Adds Dr. Peter Libby, Renowned Cardiologist and Research Pioneer in Inflammation and Cardiovascular Disease, to its Corporate Board – Nasdaq” on July 10, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Nasdaq.com and their article: “Dr. Seth Forman to Chair XBiotech’s Second Phase 2 Study of Bermekimab in Atopic Dermatitis – Nasdaq” published on July 11, 2019 as well as Benzinga.com‘s news article titled: “48 Biggest Movers From Wednesday – Benzinga” with publication date: July 05, 2019.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $285.09 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

Investors sentiment decreased to 0.91 in 2019 Q1. Its down 4.23, from 5.14 in 2018Q4. It turned negative, as 15 investors sold Steven Madden, Ltd. shares while 78 reduced holdings. 24 funds opened positions while 61 raised stakes. 79.85 million shares or 51.63% less from 165.07 million shares in 2018Q4 were reported. Moreover, American Intl Grp has 0.01% invested in Steven Madden, Ltd. (NASDAQ:SHOO) for 64,776 shares. Systematic Financial Management Limited Partnership owns 456,847 shares or 0.53% of their US portfolio. 133,413 were accumulated by California State Teachers Retirement Systems. Blackrock accumulated 11.74M shares. Fort Washington Investment Advisors Oh owns 0.17% invested in Steven Madden, Ltd. (NASDAQ:SHOO) for 435,000 shares. Emerald Mutual Fund Advisers Tru has invested 1.04% of its portfolio in Steven Madden, Ltd. (NASDAQ:SHOO). Howe Rusling invested in 0% or 208 shares. Dimensional Fund Advsrs L P holds 0.03% in Steven Madden, Ltd. (NASDAQ:SHOO) or 2.48 million shares. Neumeier Poma Invest Counsel Ltd Llc owns 1.52M shares or 4.32% of their US portfolio. Bancshares Of America De has 0% invested in Steven Madden, Ltd. (NASDAQ:SHOO). Quantbot Techs L P reported 10,500 shares or 0.03% of all its holdings. Arrowstreet Capital Partnership has invested 0.04% in Steven Madden, Ltd. (NASDAQ:SHOO). Ironwood Mngmt Ltd accumulated 45,498 shares or 1.25% of the stock. Cwm Limited Liability Corp has 0% invested in Steven Madden, Ltd. (NASDAQ:SHOO) for 101 shares. Vanguard Grp Inc holds 8.14 million shares.

Steven Madden, Ltd. designs, sources, markets, and sells fashion-forward name brand and private label footwear for women, men, and children worldwide. The company has market cap of $2.89 billion. The Company’s Wholesale Footwear segment provides footwear under Steve Madden Women’s, Madden Girl, Steve Madden Men’s, Madden, Dolce Vita, DV by Dolce Vita, Mad Love, Steven by Steve Madden, Report, Superga, Betsey Johnson, Betseyville, Steve Madden Kids, FREEBIRD by Steven, Stevies, B Brian Atwood, Blondo, and Madden NYC brands, as well as under the third party brands. It has a 21.31 P/E ratio. The companyÂ’s Wholesale Accessories segment offers Steve Madden, Steven by Steve Madden, Madden Girl, Betsey Johnson, Madden NYC, Big Buddha, B Brian Atwood, and Luv Betsey branded; and private label fashion handbags and accessories to department stores, mass merchants, value priced retailers, online retailers, and specialty stores; and markets and sells cold weather accessories, fashion scarves, wraps, and other trend accessories under the Cejon, Steve Madden, Betsey Johnson, and Big Buddha brand names, as well as private labels to department stores and specialty stores.

More notable recent Steven Madden, Ltd. (NASDAQ:SHOO) news were published by: Finance.Yahoo.com which released: “Here’s What Steven Madden, Ltd.’s (NASDAQ:SHOO) P/E Is Telling Us – Yahoo Finance” on July 18, 2019, also Nasdaq.com with their article: “Will Steven Madden (SHOO) Witness Higher Earnings in Q2? – Nasdaq” published on July 24, 2019, Finance.Yahoo.com published: “How Much Are Steven Madden, Ltd. (NASDAQ:SHOO) Insiders Taking Off The Table? – Yahoo Finance” on July 04, 2019. More interesting news about Steven Madden, Ltd. (NASDAQ:SHOO) were released by: Nasdaq.com and their article: “Steven Madden (SHOO) Earnings Expected to Grow: What to Know Ahead of Q2 Release – Nasdaq” published on July 23, 2019 as well as Globenewswire.com‘s news article titled: “Steve Madden Announces Second Quarter 2019 Earnings Conference Call – GlobeNewswire” with publication date: July 23, 2019.

Among 6 analysts covering Steven Madden (NASDAQ:SHOO), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Steven Madden had 9 analyst reports since January 31, 2019 according to SRatingsIntel. The stock of Steven Madden, Ltd. (NASDAQ:SHOO) has “Buy” rating given on Tuesday, February 19 by Loop Capital Markets. As per Thursday, March 14, the company rating was maintained by Canaccord Genuity. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, February 14. The stock of Steven Madden, Ltd. (NASDAQ:SHOO) earned “Buy” rating by Buckingham Research on Thursday, February 28. The firm has “Market Perform” rating by Telsey Advisory Group given on Thursday, January 31. FBR Capital maintained the shares of SHOO in report on Thursday, February 28 with “Buy” rating. As per Wednesday, February 27, the company rating was maintained by Susquehanna.

Steven Madden, Ltd. (NASDAQ:SHOO) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

Analysts See $-0.55 EPS for InflaRx N.V. (IFRX); MTS Systems (MTSC) Has 1.35 Sentiment

/0 Comments/in /by

MTS Systems Corporation (NASDAQ:MTSC) Logo

MTS Systems Corp (MTSC) investors sentiment increased to 1.35 in Q1 2019. It’s up 0.24, from 1.11 in 2018Q4. The ratio has increased, as 77 hedge funds started new or increased stock positions, while 57 sold and decreased positions in MTS Systems Corp. The hedge funds in our database now hold: 17.57 million shares, up from 17.30 million shares in 2018Q4. Also, the number of hedge funds holding MTS Systems Corp in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 17 Reduced: 40 Increased: 55 New Position: 22.

Analysts expect InflaRx N.V. (NASDAQ:IFRX) to report $-0.55 EPS on August, 8.They anticipate $0.43 EPS change or 358.33% from last quarter’s $-0.12 EPS. After having $-0.43 EPS previously, InflaRx N.V.’s analysts see 27.91% EPS growth. The stock increased 2.10% or $0.06 during the last trading session, reaching $2.92. About 417,563 shares traded. InflaRx N.V. (NASDAQ:IFRX) has risen 20.54% since July 28, 2018 and is uptrending. It has outperformed by 16.11% the S&P500. Some Historical IFRX News: 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018

MTS Systems Corporation supplies test systems and sensors in the Americas, Europe, and Asia. The company has market cap of $1.02 billion. The companyÂ’s Test segment offers road simulators for durability simulation; tire performance and rolling resistance measurement systems; moving road-plane systems and balances for aerodynamics measurements in wind tunnels; service to maintain the equipment; systems for the physical characterization of material properties, including ceramics, composites, and steel; and systems to test durability and performance of implants, prostheses, and other medical and dental materials and devices. It has a 24.8 P/E ratio. It also provides products, systems, and software to perform static and fatigue testing of aircraft and space vehicles; products for blades, bearings, and wind turbines; structural engineering systems, such as static and dynamic testing; and seismic simulation tables to test the design of structures and establish building codes.

Dean Capital Management holds 1.92% of its portfolio in MTS Systems Corporation for 20,955 shares. Tributary Capital Management Llc owns 447,405 shares or 1.77% of their US portfolio. Moreover, Ariel Investments Llc has 1.1% invested in the company for 1.63 million shares. The California-based Fuller & Thaler Asset Management Inc. has invested 0.87% in the stock. Dean Investment Associates Llc, a Ohio-based fund reported 109,141 shares.

Analysts await MTS Systems Corporation (NASDAQ:MTSC) to report earnings on August, 5. They expect $0.64 EPS, up 30.61% or $0.15 from last year’s $0.49 per share. MTSC’s profit will be $11.49M for 22.21 P/E if the $0.64 EPS becomes a reality. After $0.76 actual EPS reported by MTS Systems Corporation for the previous quarter, Wall Street now forecasts -15.79% negative EPS growth.

The stock increased 0.87% or $0.49 during the last trading session, reaching $56.85. About 89,453 shares traded. MTS Systems Corporation (MTSC) has risen 6.98% since July 28, 2018 and is uptrending. It has outperformed by 2.55% the S&P500. Some Historical MTSC News: 13/03/2018 – MTSC JOB CUTS DUE TO TRANSFER TO CONTRACT MANUFACTURING PARTNER; 24/04/2018 – MTS Systems at Wells Fargo Industrials Conference May 9; 23/05/2018 – MTS Systems Presenting at Conference Tomorrow; 13/03/2018 – MTSC CUTS JOBS IN CHINA TEST SEGMENT; 07/05/2018 – MTS SYSTEMS 2Q REV. $191M, EST. $195.5M (2 EST.); 07/05/2018 – MTS SYSTEMS CORP – REAFFIRM EXPECTED OUTLOOK FOR FISCAL YEAR 2018; 07/05/2018 – MTS SYSTEMS 2Q ADJ EPS 45C, EST. 48C; 22/04/2018 – DJ MTS Systems Corporation, Inst Holders, 1Q 2018 (MTSC); 13/03/2018 MTS SYSTEMS – ANNOUNCES WORKFORCE REDUCTIONS & MANUFACTURING FACILITY CLOSURES IN TEST SEGMENT RELATING TO TRANSFER OF PRODUCTION OPERATIONS IN CHINA; 07/05/2018 – MTS Systems Anticipates Restructuring Action to Be Completed by End of Fiscal Yr 2018

More notable recent MTS Systems Corporation (NASDAQ:MTSC) news were published by: Finance.Yahoo.com which released: “Introducing MTS Systems (NASDAQ:MTSC), A Stock That Climbed 33% In The Last Three Years – Yahoo Finance” on July 02, 2019, also Finance.Yahoo.com with their article: “Is MTS Systems Corporation (MTSC) A Good Stock To Buy ? – Yahoo Finance” published on June 29, 2019, Nasdaq.com published: “Technology Sector Update for 07/08/2019: MTSC,MSFT,SYMC,AVGO,AAPL – Nasdaq” on July 08, 2019. More interesting news about MTS Systems Corporation (NASDAQ:MTSC) were released by: Seekingalpha.com and their article: “MTS upsizes and prices offering of $350M of 5.750% senior unsecured notes due 2027 – Seeking Alpha” published on July 12, 2019 as well as Finance.Yahoo.com‘s news article titled: “Is MTS Systems Corporation’s (NASDAQ:MTSC) CEO Paid Enough Relative To Peers? – Yahoo Finance” with publication date: May 07, 2019.

Since January 1, 0001, it had 2 insider purchases, and 0 selling transactions for $110,654 activity.

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Finance.Yahoo.com which released: “Do Insiders Own Shares In InflaRx N.V. (NASDAQ:IFRX)? – Yahoo Finance” on July 19, 2019, also Finance.Yahoo.com with their article: “Hedge Funds Have Never Been This Bullish On InflaRx N.V. (IFRX) – Yahoo Finance” published on June 29, 2019, Seekingalpha.com published: “InflaRx up 6% after hours on additional IFX-1 data – Seeking Alpha” on July 18, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “Health Care Sector Update for 07/19/2019: GLPG,MTP,IFRX – Nasdaq” published on July 19, 2019 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 07/19/2019: MDGS,MTP,GLPG,IFRX – Nasdaq” with publication date: July 19, 2019.

MTS Systems Corporation (NASDAQ:MTSC) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

Hidradenitis Suppurativa Treatment Market Research Reports 2019 | Global Industry Size, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis by Market Reports World

/0 Comments/in /by

Hidradenitis Suppurativa Treatment

This “Hidradenitis Suppurativa Treatment Market“ report study provides key statistics on the market status of the Hidradenitis Suppurativa Treatment Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Hidradenitis Suppurativa Treatment Industry research report is a professional and in-depth study on the market size, growth, share, trends, as well as industry analysis.

Request a sample copy of the report – https://www.marketreportsworld.com/enquiry/request-sample/13679592

Hidradenitis Suppurativa Treatment Market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.According to the details of the consumption figures, the global Hidradenitis Suppurativa Treatment Market is expected to reach the value of US$ XX million at the end of 2024. Furthermore, Market size, the revenue shares of each segment and its sub-segments, as well as forecast figures are also covered in this report.

Hidradenitis Suppurativa Treatment Market Segment by Manufacturers: –

  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Pfizer
  • AbbVie
  • Allergan
  • AstraZeneca

Global Hidradenitis Suppurativa Treatment market report also presents the manufacturer’s landscape and a corresponding detailed analysis of the major manufacturers operating in the Hidradenitis Suppurativa Treatment industry. Hidradenitis Suppurativa Treatment market also provides Opportunities, Risk, and Driving Force which shows current and future market condition, to get a full detailed list, view our report.

Enquire before purchasing this report – https://www.marketreportsworld.com/enquiry/pre-order-enquiry/13679592   

About Hidradenitis Suppurativa Treatment Industry

The Global Hidradenitis Suppurativa Treatment market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hidradenitis Suppurativa Treatment market based on company, product type, end-user and key regions. This report focuses on the Hidradenitis Suppurativa Treatment in the global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The overviews, SWOT analysis and strategies of each vendor in the Hidradenitis Suppurativa Treatment market provide understanding about the market forces and how those can be exploited to create future opportunities. This research report categorizes the global Hidradenitis Suppurativa Treatment market by top players/brands, region, type and end user. This report also studies the global Hidradenitis Suppurativa Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

Hidradenitis Suppurativa Treatment Market by Types: –

  • Medications
  • Surgery
  • Others

Hidradenitis Suppurativa Treatment Market by Applications: –

Purchase this report (Price 3900 USD for a single-user license) – https://www.marketreportsworld.com/purchase/13679592    

Hidradenitis Suppurativa Treatment Market by Regions: –

North America (USA, Canada and Mexico),

Europe (Germany, France, UK, Russia and Italy),

Asia-Pacific (China, Japan, Korea, India and Southeast Asia),

South America (Brazil, Argentina, Columbia etc.),

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Industry chain analysis, raw material and end user’s information.  Global key players’ information including SWOT analysis, company’s financial figures, Laser Marking Machine figures of each company are covered. Hidradenitis Suppurativa Treatment market analysis tools used in the report include Porter’s five forces analysis, PEST analysis, drivers and restraints, opportunities and threatens. Based year in this report is 2019; the historical data is from 2014 to 2018 and forecast year is from 2019 to 2025.

Important Points in Hidradenitis Suppurativa Treatment Market Report: –

  • Introduction, product scope, market overview, growth rate, market opportunities, market risk, the market driving force
  • Key manufacturers in Hidradenitis Suppurativa Treatment, with sales, revenue, and price of Hidradenitis Suppurativa Treatment, in 2013 and 2025
  • Provides competitive situation among the top manufacturers, with sales, revenue, and market share in 2013 and 2025
  • Global Hidradenitis Suppurativa Treatment market by regions, with sales, revenue, and market share of Hidradenitis Suppurativa Treatment, for each region, from 2013 and 2025
  • Manufacturers, with sales, revenue and market share by key countries in these regions
  • Market by type and application, with sales market share and growth rate by type, application, from 2013 and 2025
  • Hidradenitis Suppurativa Treatment market forecast, by regions, type and application, with sales and revenue, from 2013 and 2025
  • Hidradenitis Suppurativa Treatment sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

The report then estimates 2013-2025 market development trends of Hidradenitis Suppurativa Treatment market. Analysis of upstream raw materials, downstream demand and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Hidradenitis Suppurativa Treatment market before evaluating its feasibility.

Browse complete table of contents at –https://www.marketreportsworld.com/TOC/13679592#TOC

About Us: –

Market Reports World is the Credible Source for Gaining the Market Reports that will Provide you with the Lead Your Business Needs. Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided today’s businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.

CONTACT US

Name: Ajay More

Email:  [email protected]

Phone: US +1 424 253 0807 /UK +44 203 239 8187

For Our Other Report:-

Cloud-based Contact Center Market 2019 Industry Overview, Key Players Analysis, Emerging Opportunities, Comprehensive Research Study, Competitive Landscape and Potential of Industry from 2019-2024

Source link

Medical News & Information

/0 Comments/in /by


This may be because of a mistyped URL, a faulty referral from another website, an out of date search engine listing, or the page may have moved. However, we’re happy to write you a referral to visit one of these MDLinx products.

Medical News Articles


All the best medical articles in 32 specialties and 800 subspecialties from over 2,000 peer-reviewed medical journals are summarized, ranked and sorted daily keep you current in less than 5 minutes a day.

ctsrcwbxfqfdaqyewyrqczdssfxccc

Smartest Doc TM


Compete in a daily competition to find out if you’re the Smartest Doc in America! Or, build your personal Review scorecard using thousands of free self-assessment questions to aid exam prep and keep you sharp.

MDLinx Career Center


Search medical job listings and have job opportunities sent directly to your email inbox. Post your CV and have the top medical recruiters bring your dream job to YOU!

Source link

Sio Capital Management Boosted Chemocentryx (CCXI) Holding; Adams Express Company Has Boosted Alexion Pharmaceuticals (ALXN) Stake by $5.33 Million

/0 Comments/in /by

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Logo

Sio Capital Management Llc increased its stake in Chemocentryx Inc (CCXI) by 213.24% based on its latest 2019Q1 regulatory filing with the SEC. Sio Capital Management Llc bought 360,918 shares as the company’s stock rose 15.42% with the market. The institutional investor held 530,175 shares of the health care company at the end of 2019Q1, valued at $7.36M, up from 169,257 at the end of the previous reported quarter. Sio Capital Management Llc who had been investing in Chemocentryx Inc for a number of months, seems to be bullish on the $449.29 million market cap company. The stock increased 2.79% or $0.21 during the last trading session, reaching $7.74. About 245,148 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 11.16% since July 28, 2018 and is uptrending. It has outperformed by 6.73% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI)

Adams Express Company increased its stake in Alexion Pharmaceuticals Inc. (ALXN) by 36.85% based on its latest 2019Q1 regulatory filing with the SEC. Adams Express Company bought 39,500 shares as the company’s stock rose 2.58% with the market. The institutional investor held 146,700 shares of the health care company at the end of 2019Q1, valued at $19.83M, up from 107,200 at the end of the previous reported quarter. Adams Express Company who had been investing in Alexion Pharmaceuticals Inc. for a number of months, seems to be bullish on the $25.70B market cap company. The stock decreased 2.88% or $3.4 during the last trading session, reaching $114.63. About 3.41M shares traded or 124.73% up from the average. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has risen 4.53% since July 28, 2018 and is uptrending. It has outperformed by 0.10% the S&P500. Some Historical ALXN News: 20/04/2018 – ALEXION: NO COMPULSORY LICENSE OF SOLIRIS REQUESTED IN BRAZIL; 21/04/2018 – DJ Alexion Pharmaceuticals Inc, Inst Holders, 1Q 2018 (ALXN); 15/03/2018 – ALEXION PHARMACEUTICALS INC – ALXN1210 WAS GENERALLY WELL TOLERATED WITH A SAFETY PROFILE THAT IS CONSISTENT WITH THAT SEEN FOR SOLIRIS; 15/03/2018 – ALEXION PHARMACEUTICALS INC – ALXN1210 ACHIEVED NON-INFERIORITY TO SOLIRIS ON CO-PRIMARY ENDPOINTS OF TRANSFUSION AVOIDANCE; 11/04/2018 – From the dawn patrol — Alexion takes its first step rebuilding the pipeline, adding a rare disease drug in $855M cash buyout $ALXN; 11/04/2018 – Alexion To Acquire Wilson Therapeutics; 02/04/2018 – ABEONA THERAPEUTICS INC – THIEL MOST RECENTLY SERVED AS EXECUTIVE VICE PRESIDENT AND CHIEF COMMERCIAL OFFICER OF ALEXION PHARMACEUTICALS, INC; 15/05/2018 – Perceptive Adds Alexion, Exits Zimmer Biomet: 13F; 20/04/2018 – $ALXN — Here is the official statement from Attorney General of the Union of Brazil “Soliris case was only the first to be tried by the STJ. Several other drugs in the same situation”; 26/04/2018 – $ALXN-1210 Ph3 Switch Study almost achieved statistical significance for superiority on primary endpoint

Investors sentiment increased to 1.44 in 2019 Q1. Its up 0.51, from 0.93 in 2018Q4. It increased, as 12 investors sold CCXI shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Panagora Asset Management Inc invested in 0.02% or 308,857 shares. Ameriprise Financial has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Element Capital Lc accumulated 11,906 shares. D E Shaw & holds 0% or 126,359 shares in its portfolio. Adams Diversified Equity Fund Inc reported 15,700 shares. Geode Capital Management Ltd Llc stated it has 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Clarivest Asset Mgmt Ltd Liability Corp owns 51,400 shares. California State Teachers Retirement System has invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). 775,123 were reported by Acadian Asset Mngmt Ltd Liability. Charles Schwab Mgmt has 49,177 shares. Morgan Stanley reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Moreover, Millennium Management Ltd has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Wasatch has invested 0.37% in ChemoCentryx, Inc. (NASDAQ:CCXI). Alliancebernstein LP reported 46,500 shares. Wells Fargo Mn reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI).

Sio Capital Management Llc, which manages about $116.75M and $370.38M US Long portfolio, decreased its stake in Hill (NYSE:HRC) by 15,000 shares to 9,682 shares, valued at $1.03M in 2019Q1, according to the filing. It also reduced its holding in Sanofi Sa (NYSE:SNY) by 111,534 shares in the quarter, leaving it with 156,854 shares, and cut its stake in Achieve Life Sciences Inc.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA – Nasdaq” on March 11, 2019, also Seekingalpha.com with their article: “ChemoCentryx And Aurinia In Focal Segmental Glomerulosclerosis: Strength In Numbers – Seeking Alpha” published on May 23, 2019, Seekingalpha.com published: “ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q1 2019 Results – Earnings Call Transcript – Seeking Alpha” on May 06, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Finance.Yahoo.com and their article: “Hedge Funds Have Never Been More Bullish On ChemoCentryx Inc (CCXI) – Yahoo Finance” published on May 09, 2019 as well as Seekingalpha.com‘s news article titled: “InflaRx downdraft engulfs ChemoCentryx, down 28% premarket – Seeking Alpha” with publication date: June 05, 2019.

Adams Express Company, which manages about $1.82B US Long portfolio, decreased its stake in Nic Inc. (NASDAQ:EGOV) by 31,600 shares to 16,500 shares, valued at $282,000 in 2019Q1, according to the filing. It also reduced its holding in First Cash Financial Services Inc. by 4,900 shares in the quarter, leaving it with 3,000 shares, and cut its stake in Essent Group Ltd. (NYSE:ESNT).

Investors sentiment increased to 1.4 in 2019 Q1. Its up 0.29, from 1.11 in 2018Q4. It increased, as 49 investors sold ALXN shares while 137 reduced holdings. 67 funds opened positions while 193 raised stakes. 207.90 million shares or 0.54% more from 206.79 million shares in 2018Q4 were reported. Hsbc Holdg Public Ltd Com has 142,343 shares. Of Vermont stated it has 19 shares or 0% of all its holdings. Colony Gp Ltd Llc accumulated 3,775 shares or 0.02% of the stock. Calamos invested 0.58% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). De Burlo Gru has 16,560 shares for 0.45% of their portfolio. Rampart Invest Mngmt Ltd Limited Liability Company accumulated 0.04% or 2,724 shares. Polar Capital Llp accumulated 0.58% or 459,092 shares. Aperio Group Limited Liability Company holds 0.04% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 74,395 shares. Apg Asset Management Nv, a Netherlands-based fund reported 57,332 shares. Pinnacle Associate Ltd holds 0.04% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 13,650 shares. Adage Cap Grp Lc holds 488,562 shares or 0.17% of its portfolio. Freestone Capital Ltd Llc stated it has 0.07% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). The Georgia-based Advisory Net Limited Com has invested 0% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Victory Cap Mgmt owns 143,067 shares for 0.04% of their portfolio. Odey Asset Gru Limited reported 18,898 shares.

More notable recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Nasdaq.com which released: “Alexion Receives FDA Approval for Label Expansion of Soliris – Nasdaq” on June 28, 2019, also Nasdaq.com with their article: “Alexion (ALXN) Moves to Strong Buy: Rationale Behind the Upgrade – Nasdaq” published on July 17, 2019, Benzinga.com published: “The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index – Benzinga” on July 24, 2019. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were released by: Nasdaq.com and their article: “3 Biotech Stocks That Could Double Your Money – Nasdaq” published on July 14, 2019 as well as Nasdaq.com‘s news article titled: “Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth – Nasdaq” with publication date: April 18, 2019.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

Health firm at ease in its own skin

/0 Comments/in /by

A Galway startup is set to revolutionise wound dressings for sufferers of rare diseases, writes Trish Dromey

Galway startup HidraMed Solutions is gearing up for an end-of-year launch of an innovative adhesive-free wound dressing.

The patent-pending dressing has been designed for use in Hidradenitis Suppurativa (HS) a debilitating skin disease which causes skin lesions and effects 1% of the global population.

Company founder and CEO Suzanne Moloney says this will be the first non-adhesive wound dressing solution on the market, created specifically for people with HS, estimated to number 650,000 in the UK and Ireland alone.

In preparation for the launch , HidraMed is in the process of raising an investment round of €1.25m in funding, which Ms Moloney says is now close to being finalised.

Since the start of the year, the company has reached an agreement with a manufacturer, carried out beta testing, and in recent weeks has taken on two new staff, one for sales and marketing and one for customer service.

“Our plan is to launch in Ireland and the UK at the end of the year and within three months to start selling in both Europe and North America,” said Ms Moloney, explaining the strategy for now is to sell directly to customers online.

Once direct sales are established, HidraMed will begin to work on business-to-business sales, supplying pharmacies and healthcare services.

Following the launch of a range of dressings for the HS market which will sell under the HidraMed brand, the company plans to follow up with the development of a range of adhesive-free dressings suitable for use across all areas of wound care, in particular for use in venous leg ulcers and sacral pressure sores.

The launch comes on foot of seven years of research and effort by Ms Moloney, a HS patient who set out in 2012 to create a better dressing for the chronic skin condition because none of the available ones worked well and all used adhesive which often exacerbated the wounds. Describing the new HidraMed dressing as simple but effective, she expects it to be a gamechanger in the chronic wound care market.

“It provides secure dressing placement and retention. Users can apply, adjust and remove a dressing quickly and easily,” she says, adding that full details of how it works are being kept under wraps until the launch.

She started working on developing a dressing while running her own bakery, but gave this up to become a full-time entrepreneur in March 2016 when she set up HidraMed.

Carrying out expensive research on chronic wound management, she spoke to 500 HS patients as well as numerous dermatologists before trying out a range of different materials for the dressing.

Over the last four years, her company has secured a total of €250,000 in funding, some of it from grant aid and some from winning business competitions.

“We received €50,000 in competitive start funding from Enterprise Ireland, another €50,000 for winning the early stage category in the InterTrade Ireland Seedcorn competition last year while the EIT Health Headstart Programme also provided us with €50,000 in funding,” said Ms Moloney.

Securing a place on Ireland’s first medical accelerator programme BioExel at NUIG last year helped speed up the company’s progress.

Operating from Galway Business Innovation Centre at NUI, the company now has four full-time staff as well as two part-time employees.

The goal for 2020 is to develop international sales of the HS wound dressing solution.

“We expect to be employing at least eight full-time staff by the end of next year and also to have a pipeline of products which will include topical creams which can be used for a variety of skin conditions,” says Ms Moloney.

Source link

Skylands Capital Has Upped Beacon Roofing Supply (BECN) Position; Inflarx N.V. (IFRX) SI Increased By 17.35%

/0 Comments/in /by

Beacon Roofing Supply, Inc. (NASDAQ:BECN) Logo

Inflarx N.V. (NASDAQ:IFRX) had an increase of 17.35% in short interest. IFRX’s SI was 443,000 shares in July as released by FINRA. Its up 17.35% from 377,500 shares previously. With 109,000 avg volume, 4 days are for Inflarx N.V. (NASDAQ:IFRX)’s short sellers to cover IFRX’s short positions. The SI to Inflarx N.V.’s float is 6.21%. The stock increased 2.10% or $0.06 during the last trading session, reaching $2.92. About 417,563 shares traded. InflaRx N.V. (NASDAQ:IFRX) has risen 20.54% since July 28, 2018 and is uptrending. It has outperformed by 16.11% the S&P500. Some Historical IFRX News: 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE

Skylands Capital Llc increased Beacon Roofing Supply Inc (BECN) stake by 3.57% reported in 2019Q1 SEC filing. Skylands Capital Llc acquired 14,350 shares as Beacon Roofing Supply Inc (BECN)’s stock rose 5.91%. The Skylands Capital Llc holds 416,350 shares with $13.39 million value, up from 402,000 last quarter. Beacon Roofing Supply Inc now has $2.56 billion valuation. The stock decreased 0.19% or $0.07 during the last trading session, reaching $37.44. About 324,970 shares traded. Beacon Roofing Supply, Inc. (NASDAQ:BECN) has declined 7.20% since July 28, 2018 and is downtrending. It has underperformed by 11.63% the S&P500. Some Historical BECN News: 03/05/2018 – Investor Expectations to Drive Momentum within Balchem, Beacon Roofing Supply, Rice Midstream Partners LP, LTC Properties, Ubiq; 27/03/2018 – Beacon Roofing at Non-Deal Roadshow Hosted By SunTrust Today; 08/05/2018 – Beacon Roofing Supply Raises Allied Synergy Target to $120M From $110M; 20/04/2018 – DJ Beacon Roofing Supply Inc, Inst Holders, 1Q 2018 (BECN); 20/03/2018 – Beacon Roofing Non-Deal Roadshow Set By SunTrust for Mar. 27; 01/05/2018 – Beacon Roofing Supply Announces Acquisition Of Minnesota-Based Tri-State Builder’s Supply; 23/05/2018 – Beacon Roofing Presenting at KeyCorp Conference May 29; 18/04/2018 – Beacon Roofing Supply to Announce Second Quarter 2018 Earnings on May 8, 2018; 01/05/2018 – BEACON ROOFING SUPPLY ACQUIRES TRI-STATE BUILDER’S SUPPLY; 08/05/2018 – BEACON ROOFING 2Q ADJ LOSS/SHR 35C, EST. LOSS/SHR 9.0C

Since March 14, 2019, it had 3 buys, and 0 sales for $345.36 million activity. Shares for $158.08M were bought by CD&R Investment Associates IX – Ltd.. FROST RICHARD W had bought 11,754 shares worth $401,634.

More notable recent Beacon Roofing Supply, Inc. (NASDAQ:BECN) news were published by: Finance.Yahoo.com which released: “What Investors Should Know About Beacon Roofing Supply, Inc.’s (NASDAQ:BECN) Financial Strength – Yahoo Finance” on July 03, 2019, also Nasdaq.com with their article: “Is Beacon Roofing Supply (BECN) a Good Value Investor Pick? – Nasdaq” published on July 18, 2019, Nasdaq.com published: “Consumer Sector Update for 07/03/2019: SAUC,TSLA,BECN,OC – Nasdaq” on July 03, 2019. More interesting news about Beacon Roofing Supply, Inc. (NASDAQ:BECN) were released by: Finance.Yahoo.com and their article: “Notable Insider Buys This Past Week: AbbVie, MGM and More – Yahoo Finance” published on June 30, 2019 as well as Nasdaq.com‘s news article titled: “Fastenal (FAST) Up 23% in 6 Months: Can the Bull Run Continue? – Nasdaq” with publication date: June 28, 2019.

Skylands Capital Llc decreased Rayonier Advanced Matls Inc (NYSE:RYAM) stake by 68,350 shares to 234,950 valued at $3.19M in 2019Q1. It also reduced Sportsmans Whse Hldgs Inc (NASDAQ:SPWH) stake by 131,675 shares and now owns 270,725 shares. Intercontinental Exchange In (NYSE:ICE) was reduced too.

Investors sentiment decreased to 0.78 in 2019 Q1. Its down 0.20, from 0.98 in 2018Q4. It dropped, as 33 investors sold BECN shares while 63 reduced holdings. 20 funds opened positions while 55 raised stakes. 67.43 million shares or 8.51% less from 73.70 million shares in 2018Q4 were reported. Tradewinds Cap Ltd holds 217 shares. Marshall Wace Llp holds 45,459 shares or 0.01% of its portfolio. Deutsche Savings Bank Ag holds 0% or 28,912 shares. Howe & Rusling holds 0% of its portfolio in Beacon Roofing Supply, Inc. (NASDAQ:BECN) for 113 shares. Commonwealth Retail Bank Of Australia accumulated 0% or 8,400 shares. Moreover, Bankshares Of America De has 0% invested in Beacon Roofing Supply, Inc. (NASDAQ:BECN) for 719,766 shares. Principal Gru holds 6,402 shares or 0% of its portfolio. Zeke Capital Advisors Ltd Liability holds 0.06% or 20,534 shares. Ironwood Inv Mgmt Ltd Com has 32,986 shares. The Massachusetts-based Rhumbline Advisers has invested 0.01% in Beacon Roofing Supply, Inc. (NASDAQ:BECN). Eagle Asset holds 0.03% or 201,316 shares. Parkside Fin Financial Bank Trust holds 93 shares or 0% of its portfolio. Fuller Thaler Asset Mngmt Inc invested 0.77% of its portfolio in Beacon Roofing Supply, Inc. (NASDAQ:BECN). Arcadia Management Mi has 70,195 shares. The Ontario – Canada-based Fincl Bank Of Montreal Can has invested 0% in Beacon Roofing Supply, Inc. (NASDAQ:BECN).

Among 6 analysts covering Beacon Roofing Supply (NASDAQ:BECN), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Beacon Roofing Supply had 9 analyst reports since February 25, 2019 according to SRatingsIntel. The firm has “Hold” rating by RBC Capital Markets given on Tuesday, March 26. J.P. Morgan maintained the stock with “Hold” rating in Tuesday, March 26 report. Buckingham Research maintained Beacon Roofing Supply, Inc. (NASDAQ:BECN) on Tuesday, March 26 with “Neutral” rating. The stock has “Buy” rating by SunTrust on Monday, March 25. The firm has “Hold” rating given on Monday, February 25 by Buckingham Research. The rating was maintained by Raymond James on Tuesday, March 26 with “Buy”. The rating was maintained by Robert W. Baird on Tuesday, March 26 with “Neutral”.

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Finance.Yahoo.com which released: “Do Insiders Own Shares In InflaRx N.V. (NASDAQ:IFRX)? – Yahoo Finance” on July 19, 2019, also Finance.Yahoo.com with their article: “Hedge Funds Have Never Been This Bullish On InflaRx N.V. (IFRX) – Yahoo Finance” published on June 29, 2019, Seekingalpha.com published: “InflaRx up 6% after hours on additional IFX-1 data – Seeking Alpha” on July 18, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “Health Care Sector Update for 07/19/2019: GLPG,MTP,IFRX – Nasdaq” published on July 19, 2019 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 07/19/2019: MDGS,MTP,GLPG,IFRX – Nasdaq” with publication date: July 19, 2019.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $75.82 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

Beacon Roofing Supply, Inc. (NASDAQ:BECN) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

What’s Ahead for XBiotech Inc. (XBIT) After Today’s Big Decline?

/0 Comments/in /by

XBiotech Inc. (NASDAQ:XBIT) Logo

The stock of XBiotech Inc. (NASDAQ:XBIT) is a huge mover today! The stock decreased 2.62% or $0.19 during the last trading session, reaching $7.06. About 79,976 shares traded. XBiotech Inc. (NASDAQ:XBIT) has risen 114.12% since July 27, 2018 and is uptrending. It has outperformed by 109.69% the S&P500.
The move comes after 7 months negative chart setup for the $289.19 million company. It was reported on Jul, 27 by Barchart.com. We have $6.50 PT which if reached, will make NASDAQ:XBIT worth $23.14 million less.

Analysts await XBiotech Inc. (NASDAQ:XBIT) to report earnings on August, 8. After $-0.16 actual earnings per share reported by XBiotech Inc. for the previous quarter, Wall Street now forecasts -6.25 % EPS growth.

More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Finance.Yahoo.com which released: “Read This Before Selling XBiotech Inc. (NASDAQ:XBIT) Shares – Yahoo Finance” on April 29, 2019, also Globenewswire.com with their article: “XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease – GlobeNewswire” published on December 12, 2018, Seekingalpha.com published: “XBiotech up 4% premarket on positive bermekimab data – Seeking Alpha” on March 05, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Seekingalpha.com and their article: “XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa – Seeking Alpha” published on January 23, 2019 as well as Seekingalpha.com‘s news article titled: “XBiotech up 13% on positive bermekimab data – Seeking Alpha” with publication date: March 01, 2019.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $289.19 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

© Copyright - HIGENIX - Hidradenitis Suppurativa Natural Treatment - All Rights Reserved.